Stocks News

LAST PRICE
18.0100
TODAY'S CHANGE (%)
Trending Up1.0100 (5.9412%)

Bid / Lots
17.4000/ 1
Ask / Lots
19.9100/ 1
Open / Previous Close
16.9400 / 17.0000
Day Range
Low 16.5500
High 18.1300
52 Week Range
Low 3.6000
High 28.1500
Volume
502,214
above average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Apr 16, 2024
- DJ Longboard Pharmaceuticals Price Target Maintained With a $60.00/Share by HC Wainwright & Co., from 10:44AM ET on Tuesday Apr 16, 2024 by Dow Jones
  10:44AM ET on Tuesday Apr 16, 2024 by Dow Jones
  Companies Mentioned: LBPH
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/LBPH/analyst-ratings
  
  (END) Dow Jones Newswires
  
  April 16, 2024 10:44 ET (14:44 GMT)
Apr 10, 2024
- DJ Longboard Pharmaceuticals Price Target Maintained With a $60.00/Share by Cantor Fitzgerald, from 9:52AM ET on Wednesday Apr 10, 2024 by Dow Jones
  9:52AM ET on Wednesday Apr 10, 2024 by Dow Jones
  Companies Mentioned: LBPH
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/LBPH/analyst-ratings
  
  (END) Dow Jones Newswires
  
  April 10, 2024 09:52 ET (13:52 GMT)
Apr 3, 2024
- Longboard Pharmaceuticals to Present Late-Breaking Data from the PACIFIC Study at the American Academy of Neurology (AAN) Annual Meeting on April 15, from 9:00AM ET on Wednesday Apr 03, 2024 by Business Wire
  9:00AM ET on Wednesday Apr 03, 2024 by Business Wire
  Companies Mentioned: LBPH
  Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that Dr. Randall Kaye, Longboard's Chief Medical Officer, will present late-breaking data from the PACIFIC Study evaluating bexicaserin, an oral, centrally acting 5-HT2C receptor superagonist, in participants with Developmental and Epileptic Encephalopathies (DEEs) at the AAN Annual Meeting taking place April 13-18, 2024, virtually and in Denver, Colorado.
- Longboard Pharmaceuticals to Present Late-Breaking Data from the PACIFIC Study at the American Academy of Neurology (AAN) Annual Meeting on April 15, from 9:00AM ET on Wednesday Apr 03, 2024 by Dow Jones
  9:00AM ET on Wednesday Apr 03, 2024 by Dow Jones
  Companies Mentioned: LBPH
  -- PACIFIC Study Phase 1b/2a clinical data to be featured in a podium presentation at an Emerging Science Session at the AAN Annual Meeting -- Data will be featured in an encore presentation at the Seventeenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII) LA JOLLA, Calif.--(BUSINESS WIRE)--April 03, 2024--
Apr 2, 2024
- Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4), from 4:00PM ET on Tuesday Apr 02, 2024 by Business Wire
  4:00PM ET on Tuesday Apr 02, 2024 by Business Wire
  Companies Mentioned: LBPH
  Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the grant of inducement awards to three new employees. The Compensation Committee of the Board of Directors of Longboard approved the grants of non-qualified stock options to purchase an aggregate of 99,500 shares of its common stock (the "Common Stock") as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

Today
- SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Cogent Biosciences, Inc. (NASDAQ: COGT), from 8 hours ago by PR Newswire
  8 hours ago by PR Newswire
  Companies Mentioned: COGT
Apr 9, 2024
- Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor, from 9:00AM ET on Tuesday Apr 09, 2024 by GlobeNewswire
  9:00AM ET on Tuesday Apr 09, 2024 by GlobeNewswire
  Companies Mentioned: COGT
Apr 8, 2024
- Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference, from 4:30PM ET on Monday Apr 08, 2024 by GlobeNewswire
  4:30PM ET on Monday Apr 08, 2024 by GlobeNewswire
  Companies Mentioned: OLMA
Apr 5, 2024
- Hillevax Insider Sold Shares Worth $264,467, According to a Recent SEC Filing, from 5:52PM ET on Friday Apr 05, 2024 by MT Newswires
  5:52PM ET on Friday Apr 05, 2024 by MT Newswires
  Companies Mentioned: HLVX
Apr 2, 2024
- Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), from 4:29PM ET on Tuesday Apr 02, 2024 by GlobeNewswire
  4:29PM ET on Tuesday Apr 02, 2024 by GlobeNewswire
  Companies Mentioned: OLMA
- Goldman Sachs Initiates Olema Pharmaceuticals at Buy With $24 Price Target, from 8:05AM ET on Tuesday Apr 02, 2024 by MT Newswires
  8:05AM ET on Tuesday Apr 02, 2024 by MT Newswires
  Companies Mentioned: OLMA
Mar 21, 2024
- Stifel Adjusts HilleVax Price Target to $34 From $30, Maintains Buy Rating, from 12:07PM ET on Thursday Mar 21, 2024 by MT Newswires
  12:07PM ET on Thursday Mar 21, 2024 by MT Newswires
  Companies Mentioned: HLVX
- HilleVax Insider Sold Shares Worth $985,536,428, According to a Recent SEC Filing, from 9:46AM ET on Thursday Mar 21, 2024 by MT Newswires
  9:46AM ET on Thursday Mar 21, 2024 by MT Newswires
  Companies Mentioned: HLVX
Mar 20, 2024
- HilleVax Proposes $500 Million Offering of Equity, Debt Securities in Shelf Registration, from 5:49PM ET on Wednesday Mar 20, 2024 by MT Newswires
  5:49PM ET on Wednesday Mar 20, 2024 by MT Newswires
  Companies Mentioned: HLVX
- HilleVax Q4 Net Loss Widens; Shares Extend Decline After Hours, from 5:49PM ET on Wednesday Mar 20, 2024 by MT Newswires
  5:49PM ET on Wednesday Mar 20, 2024 by MT Newswires
  Companies Mentioned: HLVX

Longboard Pharmaceuticals Inc
NASDAQ:LBPHUnited States

Search Criteria

Apr 16, 2024

DJ Longboard Pharmaceuticals Price Target Maintained With a $60.00/Share by HC Wainwright & Co., from 10:44AM ET on Tuesday Apr 16, 2024 by Dow Jones

Apr 10, 2024

DJ Longboard Pharmaceuticals Price Target Maintained With a $60.00/Share by Cantor Fitzgerald, from 9:52AM ET on Wednesday Apr 10, 2024 by Dow Jones

Apr 3, 2024

Longboard Pharmaceuticals to Present Late-Breaking Data from the PACIFIC Study at the American Academy of Neurology (AAN) Annual Meeting on April 15, from 9:00AM ET on Wednesday Apr 03, 2024 by Business Wire

Longboard Pharmaceuticals to Present Late-Breaking Data from the PACIFIC Study at the American Academy of Neurology (AAN) Annual Meeting on April 15, from 9:00AM ET on Wednesday Apr 03, 2024 by Dow Jones

Apr 2, 2024

Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4), from 4:00PM ET on Tuesday Apr 02, 2024 by Business Wire

Peers Headlines

Today

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Cogent Biosciences, Inc. (NASDAQ: COGT), from 8 hours ago by PR Newswire

Apr 9, 2024

Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor, from 9:00AM ET on Tuesday Apr 09, 2024 by GlobeNewswire

Apr 8, 2024

Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference, from 4:30PM ET on Monday Apr 08, 2024 by GlobeNewswire

Apr 5, 2024

Hillevax Insider Sold Shares Worth $264,467, According to a Recent SEC Filing, from 5:52PM ET on Friday Apr 05, 2024 by MT Newswires

Apr 2, 2024

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), from 4:29PM ET on Tuesday Apr 02, 2024 by GlobeNewswire

Goldman Sachs Initiates Olema Pharmaceuticals at Buy With $24 Price Target, from 8:05AM ET on Tuesday Apr 02, 2024 by MT Newswires

Mar 21, 2024

Stifel Adjusts HilleVax Price Target to $34 From $30, Maintains Buy Rating, from 12:07PM ET on Thursday Mar 21, 2024 by MT Newswires

HilleVax Insider Sold Shares Worth $985,536,428, According to a Recent SEC Filing, from 9:46AM ET on Thursday Mar 21, 2024 by MT Newswires

Mar 20, 2024

HilleVax Proposes $500 Million Offering of Equity, Debt Securities in Shelf Registration, from 5:49PM ET on Wednesday Mar 20, 2024 by MT Newswires

HilleVax Q4 Net Loss Widens; Shares Extend Decline After Hours, from 5:49PM ET on Wednesday Mar 20, 2024 by MT Newswires